Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Life Sci Space Res (Amst). 2021 Nov;31:85-91. doi: 10.1016/j.lssr.2021.09.001. Epub 2021 Sep 10.
Inevitable exposure to high-LET ionizing radiation (IR) present in galactic cosmic radiation (GCR) could enhance gastrointestinal (GI) cancer incidence among astronauts undertaking deep space exploration and GI-cancer mortality has been predicted to far exceed NASA's limit of < 3% REID (Radiation exposure-induced death) from cancer. Therefore, the development of countermeasure agents against high-LET radiation-induced GI cancer is needed to safeguard astronauts during and after an outer space mission. The cyclooxygenase-2/prostaglandin E2 (COX2/PGE2) mediated activation of pro-inflammatory and oncogenic signaling has been reported to play an important role in persistent inflammation and GI-tumorigenesis after high-LET radiation exposure. Therefore, aspirin, a well-known inhibitor of the COX/PGE2 pathway, was evaluated as a potential countermeasure against Si-induced PGE2 and tumorigenesis in Apc, a murine model of human GI-cancer. Animals were fed either standard or aspirin supplemented diet (75, 150, or 300 mg/day of human equivalent dose) starting at the age of 4 weeks and continued till the end of the study, while mice were exposed to Si-ions (300 MeV/n; 69 keV/μm) at the age of 8 weeks. Serum PGE2 level, GI tumor size (>2mm), number, and cluster (>5 adjoining tumors) were analyzed at 150 days post-exposure. Aspirin led to a significant reduction in PGE2 in a dose-dependent manner but did not reduce Si-induced GI tumorigenesis even at the highest (300 mg/day) dose. In summary, this study suggests that aspirin could reduce high-LET IR-induced pro-inflammatory PGE2 levels, however, lacks the ability to reduce high-LET IR-induced GI tumorigenesis in Apc mice.
不可避免地会接触到银河宇宙辐射(GCR)中存在的高传能线密度(LET)电离辐射(IR),这可能会增加宇航员在进行深空探索时患胃肠道(GI)癌症的几率,并且 GI 癌症的死亡率预计将远远超过美国宇航局(NASA)规定的<3%的辐射诱发死亡(REID)癌症发生率。因此,需要开发针对高 LET 辐射诱导的 GI 癌症的对策药物,以在太空任务期间和之后保护宇航员的安全。据报道,环氧合酶-2/前列腺素 E2(COX2/PGE2)介导的促炎和致癌信号的激活在高 LET 辐射暴露后持续性炎症和 GI 肿瘤发生中发挥重要作用。因此,作为 COX/PGE2 途径的知名抑制剂,阿司匹林被评估为针对 Si 诱导的 PGE2 和 Apc(人类 GI 癌症的小鼠模型)肿瘤发生的潜在对策。动物从 4 周龄开始分别喂食标准或阿司匹林补充饮食(每天 75、150 或 300mg 的人等效剂量),并持续到研究结束,而小鼠在 8 周龄时接受 Si 离子(300 MeV/n;69 keV/μm)照射。在暴露后 150 天分析血清 PGE2 水平、GI 肿瘤大小(>2mm)、数量和簇(>5 个相邻肿瘤)。阿司匹林以剂量依赖性方式显著降低 PGE2,但即使在最高(300mg/天)剂量下也不能降低 Si 诱导的 GI 肿瘤发生。总之,本研究表明,阿司匹林可以降低高 LET IR 诱导的促炎 PGE2 水平,但缺乏降低 Apc 小鼠中高 LET IR 诱导的 GI 肿瘤发生的能力。